Tigecycline Pharmacokinetics Basics
Tigecycline, a glycylcycline antibiotic, has nonlinear pharmacokinetics driven primarily by non-renal clearance. About 59% of the dose undergoes biliary/fecal elimination, with only 33% renal clearance, making it suitable for patients with kidney impairment.[1] Clearance (CL) is saturable due to hepatic uptake via OATP1B1 transporters and metabolism via CYP3A4, leading to disproportionate AUC increases at higher doses (e.g., 100 mg vs. 50 mg loading).[2]
How Calculators Model Tigecycline Clearance
Pharmacokinetic (PK) calculators, such as those in InsightRX Nova, BestDose, or population PK tools like NONMEM, use compartmental models to estimate tigecycline clearance. They typically apply:
- Two-compartment models with Michaelis-Menten kinetics: Clearance is modeled as CL = Vmax / (Km + C), where Vmax is maximum elimination rate, Km is concentration at half Vmax, and C is plasma concentration. This captures saturation observed in clinical data (Km ≈ 0.5-1 mg/L).[3]
- Population PK parameters: Base CL is scaled by body size (e.g., CL/F = 14.9 L/h for 70 kg adult), adjusted for covariates like age, sex, weight, and liver function (Child-Pugh score).[4]
- Bayesian estimation: Tools incorporate patient-specific data (e.g., serum levels, dose history) to update priors from studies like 300 or ATTACH, refining CL predictions.
For example, in obese patients, calculators normalize to ideal body weight (IBW) or fat-free mass since tigecycline distribution favors hydrophilic compartments.
Adjustments for Patient Factors
- Renal impairment: Minimal adjustment needed; no dose change for CrCL <80 mL/min as renal CL is low (~20-30% of total).[5]
- Hepatic dysfunction: Reduce maintenance dose by 50% in Child-Pugh B/C; calculators halve Vmax or apply multiplicative factors (e.g., CL reduced 25-40%).[2]
- Critical illness: Augmentation via continuous renal replacement therapy (CRRT) adds diffusive/dialytic clearance (1-3 L/h); models include extracorporeal terms like CLCRRT = Qf * (1 - e^(-Ka * A/V)) where Qf is filtrate rate.[6]
- Drug interactions: Upregulation of CYP3A4 (e.g., rifampin) increases CL; calculators apply 20-50% hikes based on interaction databases.
Validation and Limitations
Models are validated against Phase 3 trials (e.g., f_%T>MIC >30% for efficacy), but calculators underperform in augmented renal clearance (ARC, CrCL >130 mL/min) or severe obesity, where measured levels are advised over predictions.[7] Tools like the FDA label-based nomogram or mwPharm integrate these for dosing simulations.
[1]: FDA Tigecycline Label
[2]: Clin Pharmacokinet 2005;44(4):397-415
[3]: Antimicrob Agents Chemother 2006;50(11):3701-7
[4]: J Antimicrob Chemother 2013;68(9):2070-6
[5]: Ther Drug Monit 2010;32(5):595-601
[6]: Crit Care 2014;18:R41
[7]: Pharmacotherapy 2019;39(7):889-902